Drawing for Serial No. 87802745

USPTO serial 87802745

Serial No. 87802745

Reviewed by CopyMark Law Group

Reg. 5754567Status 705Registered
Filing date
Status date
Registration date
May 21, 2019
Examiner
WATTS-FITZGERALD, CAITLIN C
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.

Status 705: Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights.

Need help with Serial No. 87802745?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Allison R. Imber

Allison R. Imber Allen, Dyer, Doppelt & Gilchrist, P.A.255 S. Orange Avenue, Suite 1401Orlando, FL 32801United States

Goods and services

ClassDescriptionStatusFirst use
005[ Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Pharmaceuticals, medical and veterinary preparations, pharmaceutical preparations and formulations, and medicated health preparations, all of the aforesaid goods for use in the treatment or prevention of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for use in the treatment or prevention of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions; Diagnostic preparations and biomarker reagents for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions ]SECTION 8 - CANCELLED—
010[ Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, circulatory, respiratory, endocrine, neurologic, cardiovascular, alimentary, pulmonary, musculoskeletal, lymphatic or gastrointestinal diseases, disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, bone sensory, viral, urinary, renal, metabolic or central nervous system diseases disorders and conditions, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit; Diagnostic apparatus for the diagnosis or prognosis of human and animal diseases, disorders and conditions, namely, infectious, auto-immune or immune-related, cell-proliferative or oncologic diseases, disorders and conditions, cancers, tumours and metastases, and for the diagnosis or prognosis of complications associated with such diseases, disorders and conditions, specifically, sample-analysis devices and related data-analysis software sold as a unit, nucleic acid-analysis or protein-analysis diagnosis apparatus, and diagnostic apparatus utilizing a diagnostic or prognosis algorithm and related algorithm software sold as a unit ]SECTION 8 - CANCELLED—
042Scientific services, namely, scientific research, analysis and testing in the fields of biology, chemistry or medicine, as well as in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Scientific services, namely, scientific research, analysis and testing in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus [ ; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, as well as for controlling and managing patient medical information, with any of the aforementioned services for use in the fields of biology, chemistry or medicine, as well as for use in the fields of immunology, oncology, molecular biology, cellular biology, biochemistry and medicinal chemistry; Design and development of computer software for database management, cloud-storage of data, data-management, data-query, data-analysis and data-presentation, as well as for the query, analysis and presentation of the sequence or structure of molecules, or for predicting or providing a medical diagnosis or prognosis, with any of the aforementioned services for use in the fields of discovery and development of pharmaceuticals, medical and veterinary preparations, diagnostic preparations and biomarker reagents, and diagnostic apparatus ]ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 30, 2025NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 30, 2025C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 30, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 21, 2025E815TEAS SECTION 8 & 15 RECEIVED—
May 21, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Feb 8, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 8, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Feb 8, 2024EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Feb 8, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 8, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 8, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 8, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 6, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 6, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 6, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Mar 6, 2023EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Mar 6, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 6, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Mar 6, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 8, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 8, 2021EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Oct 8, 2021EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Oct 8, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 8, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 21, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 5, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 5, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 13, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 25, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 19, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 18, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 18, 2019ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Dec 20, 2018GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Dec 20, 2018GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 20, 2018CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 12, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 12, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 4, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 6, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 6, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 6, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 4, 2018DOCKASSIGNED TO EXAMINER—
Apr 3, 2018AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Mar 30, 2018ALIEASSIGNED TO LIE—
Mar 16, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Feb 27, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 26, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 22, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance